Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

This study has been completed.
Sponsor:
Information provided by:
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT00065351
First received: July 21, 2003
Last updated: September 22, 2009
Last verified: September 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2007
  Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
No publications provided by Celgene Corporation

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):